withanoside IV: a withanolide glycoside from Ashwagantha (root of Withania somnifera), an Ayurvedic medicine; improves hindlimb function by facilitating axonal growth and increase in peripheral nervous system myelin level after spinal cord injury [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Flora | Rank | Flora Definition | Family | Family Definition |
---|---|---|---|---|
Withania | genus | A plant genus of the family SOLANACEAE. Members contain withanolides. Withania somnifera is the source of ashwagandha and aswal.[MeSH] | Solanaceae | A plant family of the order SOLANALES, class MAGNOLIOPSIDA. Among the most noted are POTATOES; TOMATOES; CAPSICUM (green and red peppers); TOBACCO; and BELLADONNA.[MeSH] |
ID Source | ID |
---|---|
PubMed CID | 71312551 |
SCHEMBL ID | 16365858 |
MeSH ID | M0515058 |
Synonym |
---|
362472-81-9 |
withanoside iv |
unii-156gup486t |
ergosta-5,24-dien-26-oic acid, 3-((6-o-beta-d-glucopyranosyl-beta-d-glucopyranosyl)oxy)-1,22,27-trihydroxy-, sigma-lactone, (1alpha,3beta,22r)- |
156GUP486T , |
withanoside iv, (+)- |
ergosta-5,24-dien-26-oic acid, 3-((6-o-.beta.-d-glucopyranosyl-.beta.-d-glucopyranosyl)oxy)-1,22,27-trihydroxy-, .sigma.-lactone, (1.alpha.,3.beta.,22r)- |
withanoside iv [usp-rs] |
(1alpha,3beta,22r)-1,26-dihydroxy-27-oxo-22,27-epoxyergosta-5,24-dien-3-yl 6-o-beta-d-glucopyranosyl-beta-d-glucopyranoside |
DTXSID40746874 |
SCHEMBL16365858 |
withanoside iv, analytical standard |
withanoside iv, united states pharmacopeia (usp) reference standard |
(2r)-2-[(1s)-1-[(1s,3r,8s,9s,10r,13s,14s,17r)-1-hydroxy-10,13-dimethyl-3-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a] |
Q27251700 |
AKOS040762510 |
Excerpt | Reference | Relevance |
---|---|---|
"Oral treatment with withanoside IV improved locomotor functions in mice with SCI." | ( [Overcoming several neurodegenerative diseases by traditional medicines: the development of therapeutic medicines and unraveling pathophysiological mechanisms]. Tohda, C, 2008) | 0.66 |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (66.67) | 29.6817 |
2010's | 1 (16.67) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (32.16) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (16.67%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (83.33%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |